• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

    5/1/25 7:45:00 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email

    Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm EST

    Marlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers.

    Phio's presentation and live Q&A will take place on Wednesday, May 7, 2025, at 2:00 pm EST in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc. A replay of the event may be accessed on the Renmark Financial Communications Inc. website at https://www.renmarkfinancial.com/vndrs.

    "All stakeholders, investors, and other individual followers are invited to join this event to learn more about Phio Pharmaceuticals and our continuing pursuit of innovative pathways towards a cancer free future using our Intasyl technology," stated Robert Bitterman, CEO and Chairman of Phio Pharmaceuticals.

    REGISTER HERE:

    Renmark Virtual Non-Deal Roadshow: NASDAQ - PHIO | Event Registration | Renmark Financial Communications

    Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.

    About Phio Pharmaceuticals Corp.
    Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company advancing its INTASYL® gene silencing technology focused on immuno-oncology therapeutics. Phio's INTASYL compounds are designed to enhance the body's immune cells to more effectively kill cancer cells. Phio's lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The on-going Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.

    For additional information, visit the Company's website, www.phiopharma.com.

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as "intends," "believes," "anticipates," "indicates," "plans," "expects," "suggests," "may," "would," "should," "potential," "designed to," "will," "ongoing," "estimate," "forecast," "target," "predict," "could" and similar references, although not all forward-looking statements contain these words. Examples of forward-looking statements contained in this press release include, among others, the possibility that our INTASYL® siRNA gene silencing technology will make the body's immune cells more effective in killing cancer cells and statements regarding our commercial and clinical strategy, development plans and timelines and other future events.

    These statements are based only on our current beliefs, expectations and assumptions and are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results may differ materially from those indicated in the forward-looking statements as a result of a number of important factors, including, but not limited to, the impact to our business and operations by inflationary pressures, rising interest rates, recession fears, the development of our product candidates, results from our preclinical and clinical activities, our ability to execute on business strategies, our ability to develop our product candidates with collaboration partners, and the success of any such collaborations, the timeline and duration for advancing our product candidates into clinical development, the timing or likelihood of regulatory filings and approvals, the success of our efforts to commercialize our product candidates if approved, our ability to manufacture and supply our product candidates for clinical activities, and for commercial use if approved, the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platform, our ability to obtain future financing, market and other conditions and those identified in our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption "Risk Factors" and in other filings the Company periodically makes with the SEC. Readers are urged to review these risk factors and to not act in reliance on any forward-looking statements, as actual results may differ from those contemplated by our forward-looking statements. Phio does not undertake to update forward-looking statements to reflect a change in its views, events or circumstances that occur after the date of this release, except as required by law.

    Contact:
    Phio Pharmaceuticals Corp.
    Jennifer Phillips: [email protected]
    Corporate Affairs

    Renmark Financial Communications Inc.
    James R. Kautz: [email protected]
    Tel: (416)-644-2020 or (212)-812-7680
    www.renmarkfinancial.com

    Corporate Logo

    To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250330

    Get the next $PHIO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      6/14/21 6:22:20 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

      5/1/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

      Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

      2/20/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update

      Marlborough, Massachusetts--(Newsfile Corp. - August 14, 2024) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical stage biotechnology company whose proprietary INTASYL™ siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today reported its financial results for the quarter ended June 30, 2024 and provided a business update.Recent Corporate UpdatesThe Phase 1b clinical trial for our lead product candidate, PH-762, received a positive safety recommendation from the Safety Monitoring Committee (SMC). There were no dose-limiting toxicities, or clinically relevant treatment-emergent adverse events in the initial cohort receiving intratumora

      8/14/24 5:00:00 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, Pres & CEO Bitterman Robert J bought $7,446 worth of shares (4,200 units at $1.77), increasing direct ownership by 22% to 23,649 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      5/23/25 9:04:08 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $4,550 worth of shares (2,500 units at $1.82), increasing direct ownership by 23% to 13,166 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      5/21/25 4:13:14 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Deming David H

      3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      3/4/25 4:58:30 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    SEC Filings

    See more
    • SEC Form 10-Q filed by Phio Pharmaceuticals Corp.

      10-Q - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      5/15/25 4:34:57 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      5/15/25 4:31:19 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      5/7/25 4:15:15 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

      Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Mr. Bitterman will also host one-on-one meetings with investors at the conferen

      5/19/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update

      Clinical trial advances for INSTASYL siRNA lead product candidate PH-762 4th Cohort enrolling and treating patients in on-going clinical studyMarlborough, Massachusetts--(Newsfile Corp. - May 15, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biopharmaceutical company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio today reported its financial results for the quarter ended March 31, 2025 and provided a business update.Recent Corporate UpdatesPH-762 Clinical ProgressPhio's ongoing Phase 1b dose escalation clinical trial (NCT 06014086) is designed to evaluat

      5/15/25 4:15:00 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Positive Pathology Results in Third Cohort in INTASYL PH-762 Skin Cancer Clinical Trial

      Complete Pathologic Response reported in 2 patients in the Third Cohort with cutaneous squamous cell carcinoma, complementing results in prior cohort Phio to present trial results to date at a podium presentation at Society for Investigative Dermatology (SID) Annual Meeting on May 10thMarlborough, Massachusetts--(Newsfile Corp. - May 7, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that a complete pathologic response (100% tumor clearance) has been reported for 2 of 3 patients with cutaneous squamous cell carcinoma (

      5/7/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      11/13/24 11:20:45 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/6/24 10:30:10 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/8/23 6:07:04 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, Pres & CEO Bitterman Robert J bought $7,446 worth of shares (4,200 units at $1.77), increasing direct ownership by 22% to 23,649 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      5/23/25 9:04:08 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $4,550 worth of shares (2,500 units at $1.82), increasing direct ownership by 23% to 13,166 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      5/21/25 4:13:14 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President & CEO Bitterman Robert J bought $740 worth of shares (1,000 units at $0.74), increasing direct ownership by 5% to 20,990 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/24 5:00:11 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care